Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 251c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($2.77), $2.51 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $30.01 million versus the consensus estimate of $37.84 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance